Clinical Trial Update: Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating pomalidomide with dose-adjusted EPOCH, with or without rituximab, for HIV-associated lymphomas; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma
• Plasmablastic Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• Etoposide (Etoposide)
• PREDNISONE (Prednisone)
• Pomalidomide (Pomalidomide)
• Rituximab (rituximab)
• Vincristine (vincristine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma | Phase 1 | Status: RECRUITING